Primary Peritoneal Carcinosarcoma
Associated Genetic Biomarkers
NCI Definition: An extremely rare and highly aggressive malignant neoplasm arising from the peritoneum. Morphologically, it is a high grade tumor, composed of carcinomatous and sarcomatous elements. 
There are 6 clinical trials for primary peritoneal carcinosarcoma, of which 6 are open and 0 are completed or closed. Of the trials that contain primary peritoneal carcinosarcoma as an inclusion criterion, 2 are phase 1 (2 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (1 open).
ERBB2 is the most frequent gene inclusion criterion for primary peritoneal carcinosarcoma clinical trials .
Cisplatin, paclitaxel, and pembrolizumab are the most common interventions in primary peritoneal carcinosarcoma clinical trials.
Significant Genes in Primary Peritoneal Carcinosarcoma
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for primary peritoneal carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and primary peritoneal carcinosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.